glp 1 アゴニスト New GLP-1 Guidelines for Type 2 Diabetes in 2025 Current Insights, Advantages and Challenges

Understanding pricing structures across providers is essential for informed access decisions, especially when genetic and biomarker data can contextualize treatment value

Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy

Nearly 4 in 10 people surveyed in a May 2024 poll by nonprofit health policy research organization KFF said theyve taken a GLP-1 solely for weight loss

Trends in Biochemical Sciences, 32(1), 12-19

Originally designed to treat diabetes and help with weight loss, GLP-1 (glucagon-like peptide 1) agonists are being tested against a number of diseases as scientists explore their wide-ranging effectsand pharmaceutical companies look to make even more profits from the burgeoning wonder drugs